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OBJECTIVES: To evaluate the cost-utility of the anemia induced
by chemotherapy treatment, with and w/o Epoetin (EPO), in
oncologic patients from the perspective of the Spanish National
Health System (NHS). METHODS: Cost-Utility analysis model
(cost per quality-adjusted life-year, QALY) in oncology patients
treated with EPO for 2.48 months (range 1.33–5.00 months).
The estimation of use and consumption of health resources
(including units of red blood cell concentrates, transfusions, and
subcutaneous administration of EPO), with and w/o EPO, was
done with the information provided from a panel of Spanish
Onco-hematologists. The adverse events rate (thrombocytope-
nia, venous thromboembolism, and others) as well as the fre-
quency of complications due to blood transfusions (pulmonary
toxicity, hemolysis, viral and bacterial infections) and the utili-
ties, with or without EPO, were obtained from a bibliographic
systematic review. Costs of health resources were obtained from
Spanish databases of health costs. A base case was evaluated,
considering average costs, and a univariant sensitivity analysis.
RESULTS: In the base case, health costs of anemia in patients
treated or not with EPO was €3893 and €2329, respectively, with
an EPO incremental cost of €1564. Assuming that an increase of
0.1114 (0.0300–0.3100) QALYs is the EPO beneﬁt, the cost per
QALY gained would be €14,040 (€5045–52,133), with all type
of tumors included in the analysis. When only solid tumors were
evaluated, excluded haematologic tumors, cost per QALY gained
was €11,849 (€6,250–17,795) and EPO would be cost-effective
in any case. CONCLUSIONS: According to the model assump-
tions, the treatment with EPO for anemia induced by chemo-
therapy could be cost-effective in Spain. Currently there is a
ongoing prospective study that will allow to clariﬁcation of this
question using real clinical data.
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OBJECTIVES: A decision-analytic model was developed to esti-
mate the cost-utility of once-daily OROS® hydromorphone
(HM) against other oral opioids in ﬁve European countries
(Germany, Denmark, Slovakia, Portugal, and Italy). METHODS:
The decision-analytic cost-utility model was developed to esti-
mate the direct medical costs and quality-adjusted life-years
(QALYs) gains associated with once-daily OROS® HM versus
sustained-release (SR) morphine, controlled-release (CR) oxyc-
odone, and twice-daily HM over a 1-year time horizon in the
management of severe chronic malignant and non-malignant
pain. CR oxycodone is not available in Portugal and twice-daily
HM is not available in Portugal and Italy, therefore, they were
not considered in those countries. RESULTS: Results from the
model demonstrate that for the management of severe chronic
non-malignant pain, OROS® HM is cost-effective in all markets
when compared to SR morphine or CR oxycodone. Compared to
SR morphine, incremental cost-effectiveness ratios (ICERs)
ranged from €6624/QALY (Slovakia) to €10,480/QALY (Italy).
Compared to CR oxycodone, ICERs ranged from €1191/QALY
(Germany) to €8559/QALY (Italy). Compared to twice-daily
HM, OROS® HM was dominant (Germany, Slovakia) or had a
minimal ICER (Denmark ICER €1048/QALY). For the manage-
ment of severe chronic malignant pain, comparing OROS® HM
to SR morphine, the ICER was highest in Portugal (€21,456/
QALY) and was below €13,500/QALY in the remaining coun-
tries. Compared to CR oxycodone, OROS® HM was dominant
(Germany) or cost-effective with ICERs that ranged from
€1399€/QALY (Denmark) to €10,651/QALY (Italy). OROS®
HM was dominant versus twice-daily HM in all countries. CON-
CLUSIONS: This model demonstrates that OROS® HM is a
cost-effective alternative to widely used oral opioids such as SR
morphine and CR oxycodone in the management of severe
chronic non-malignant and malignant pain in all ﬁve countries. It
also showed that OROS® HM is less costly and more effective
than twice-daily HM in all countries but Denmark in which the
ICER in non-malignant pain was minimal.
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OBJECTIVES: Factor concentrates composed of human blood
plasma carry the risk of transmitting blood-borne pathogens.
This study evaluated health and economic consequences of infec-
tion in haemophilia A patients in the event of a novel pathogen
emerging that can be transmitted through blood products.
METHODS: A decision analytic model was constructed to
explore consequences and costs of new pathogen emergence. The
population considered was all patients with haemophilia A
requiring Factor VIII prophylaxis in Sweden. The annual risk of
a new pathogen emerging was estimated as the average rate of
new agent emergence reported by the World Health Organisa-
tion. The percentage of the population likely to be infected was
varied reﬂecting uncertainty around reduced use of human pro-
teins in newer factor VIII products. The impact of resulting
infections on length and quality of life was estimated using
quality adjusted life years, taking mean values for historical
infections as a base case. RESULTS: Over 20 years the World
Health Organisation reported 30 newly identiﬁed diseases, of
which 5 were transmissible by transfusion. The annual risk that
a new blood-born pathogen will emerge was estimated to be
16.7%. If 5% of patients were infected economic loss would be
0.05 QALYs and €6000 per patient. If all patients were infected
the economic loss was estimated to exceed €100,000 and 1.06
QALYs per patient treated. Over 80% of the economic loss is
reduced productivity. The model ﬁndings are sensitive to the
expected rate of new pathogen emergence. CONCLUSIONS:
New blood-born pathogens emerge frequently. The model esti-
mated that the health and economic consequences of transmis-
sion of a new pathogen may be severe. Even at low levels of
infection risk, measures to further reduce the likely percentage of
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